PolyNovo (PNV): The Short Squeeze Is Already Underway — 24 Million Shares Covered in 10 Trading Days
PolyNovo's short position has collapsed from an all-time high of 14.61% to 11.15% in just 10 trading days, with 24 million shares covered. The squeeze that bears feared — and bulls waited for — has begun. Here's a full breakdown of what happened, why it's happening now, and whether the 77 million shares still short means there's more to come.
When we wrote about PolyNovo (ASX: PNV) in March 2026, short interest had just hit a record 13.26%. We warned that 91 million shares were sold short, that days-to-cover was one of the highest on the ASX, and that the squeeze potential was real but required a genuine catalyst.
The catalyst arrived. And the squeeze has begun.
Between 12 May and 25 May 2026 — just 10 trading days — 23.9 million PNV shares were covered. The short position fell from an all-time high of 14.61% (100.9 million shares) to 11.15% (77.0 million shares), according to ASIC short position disclosures aggregated on ASXShort.app. That's a $30 million unwind of the short book in under two weeks, and the stock has recovered significantly from its early-2026 lows.
But here's the thing: the job isn't done. There are still 77 million shares short. Days to cover sits at 22.7. And the narrative that drove shorts to record levels has fundamentally changed.
From Record Short to Covering Panic: The Full Timeline
To appreciate just how dramatic the recent shift has been, here's the complete arc of PNV's short position over the past year:
| Period | Short % | Shares Short | What Was Happening |
|---|---|---|---|
| May 2025 | 10.6% | 73.5M | Shorts building methodically |
| Aug 2025 | 11.89% | 82.2M | Continued accumulation |
| 19 Sep 2025 | 9.93% | 68.6M | Index removal — shorts used ETF flow as cover |
| Oct 2025 | 10.70% | 73.9M | Rebuilt quickly after index event |
| Feb 2026 | 12.89% | 89.0M | H1 results approaching — bears press |
| Mar 2026 | 13.26% | 91.6M | Previous all-time high at record writing |
| 30 Mar 2026 | 14.25% | 98.4M | New all-time high |
| 12 May 2026 | 14.61% | 100.9M | Absolute peak — 100+ million shares short |
| 25 May 2026 | 11.15% | 77.0M | ← Today. 23.9M covered in 10 days |
Let that sink in. Shorts added another 9.3 million shares between the March post and May 12 — pushing past the symbolic 100 million share mark and to 14.61%, the highest short interest PNV has ever recorded. Then, in 10 trading days, nearly a quarter of the entire short position evaporated.
What Triggered the Covering?
Short covering doesn't happen at this scale without a reason. Three interlocking events drove the unwind:
1. The ASX Price Query — 14 May 2026
On 14 May 2026, the ASX issued a price and volume query to PNV (ASX announcement: "Response to ASX Price Query", 14 May 2026). The stock had been moving before any announcement. PNV's response was clean: no undisclosed price-sensitive information, full compliance with Listing Rule 3.1.
But the query itself was significant. Regulators don't query stocks unless something unusual is happening. The query confirmed what the daily short sale volumes were already suggesting: there was aggressive activity in the stock. Whether it was early short covering, informed buying, or simply momentum feeding on itself, the ASX noticed — and that attention focuses the market.
The timing matters: short covering accelerated dramatically in the days following the query. By May 15, the single-day short sales volume hit 1.924 million — the highest in over two months — suggesting a mixture of new shorts chasing the move and existing shorts scrambling to exit.
2. H1 FY26 Results: The Catalyst That Arrived
In January, we predicted that a strong H1 result would be the squeeze catalyst. It was. PNV's H1 FY26 results, released 20 February 2026 (ASX: Appendix 4D & H1 FY26 Financial Statements), showed:
- Group sales: A$68.2M — up 26.0% year-on-year
- US sales: A$51.7M — up 25.3% (the core bear thesis challenged)
- NovoSorb MTX sales: A$6.2M — up 195.2% (new product gaining serious traction)
- Adjusted EBITDA: A$4.7M — up 82.0%
The US growth number is particularly meaningful. Bears had argued that US penetration was plateauing and that 25%+ growth would prove unsustainable. H1 FY26 delivered 25.3% US growth. The core short thesis took a direct hit. Not fatal — but enough to make the most conviction-lite shorts reassess their positions.
The NovoSorb MTX number — the single-stage grafting product that received FDA 510(k) clearance — growing 195% in one half is genuinely exceptional. This is a new commercial leg forming under the existing BTM business. The total addressable market expands meaningfully with every surgeon who adopts MTX.
3. UBS Ceased as a Substantial Holder
Per ASX substantial holder disclosures, UBS Group AG became a substantial holder in PolyNovo effective 15 May 2026 (announced 19 May) at 5.42%, with the interest largely held through securities borrowing and lending activities. Just three days later, on 18 May 2026 (announced 20 May), UBS ceased to be a substantial holder.
What this means in practice: UBS built up, then unwound, a significant lending/borrowing position around the period of maximum short interest. This is consistent with a prime broker managing the unwind of short positions held by clients — not necessarily UBS's own proprietary trade, but clients whose borrowed shares flow through UBS's books. When a substantial lending position is fully returned within three days of being disclosed, it signals that the underlying short positions were being closed out.
Who's Still Short — And Why They're Trapped
Despite the 23.9 million share cover, 77 million shares remain short. At a price of $1.255 and with days-to-cover at 22.7, these are the most stubborn bears on the ASX.
The securities lending data reveals the ecosystem:
Top borrowers (facilitating short positions):
| Institution | Shares Borrowed |
|---|---|
| Merchant Group Trust | 60,000,000 |
| State Street Global Advisors | 24,857,178 |
| Citibank N.A. Sydney Branch | 23,277,478 |
| UBS AG Australia Branch | 17,431,002 |
| J.P. Morgan Securities LLC | 13,463,319 |
The Merchant Group Trust position of 60 million shares — both lent and borrowed in equal measure — is a structural feature of the securities lending market, not a directional bet. The real directional exposure is distributed across 26 separate borrowing entities.
This distribution is both a protection and a problem for shorts. Protection: no single entity controls enough of the borrow to trigger a recall. Problem: when covering begins in earnest, 26 separate entities are simultaneously trying to buy in the same relatively illiquid stock.
Days to cover is currently 22.7 — meaning at the 30-day average daily volume of 3.5 million shares, it would take over 22 trading days to unwind the entire remaining short position. That's across a calendar month-plus of trading. If even a moderate catalyst hits and volume picks up to 5–7 million per day, you're still looking at 11–15 days of short-covering demand baked into the market structure.
The New Bull Case: Different Than Before
The bull case in January and March was largely a valuation argument — stock too beaten up, directors buying, growth intact. The bull case now is different: it's a structural short-covering argument with a changed fundamental backdrop.
Here's what's changed since the March post:
1. Price has recovered substantially from early-2026 lows. PNV's 52-week range is $0.865–$1.665. The stock has climbed well off its lows, meaning shorts who entered at lower prices are watching profit margins compress, while those who built positions in late 2025 or early 2026 near current levels or above are increasingly underwater.
2. New CSO hired from CSL. On 21 April 2026 (ASX announcement), PNV appointed Dr. Marthe D'Ombrain as Chief Scientific Officer. Per the ASX filing, she brings 20+ years of R&D experience from CSL. This signals genuine ambition in the R&D pipeline, particularly around NovoSorb MTX and the diabetes programme.
3. New non-executive director. Dr. Charmaine Gittleson joined the board effective 1 April 2026 (ASX announcement 24 March 2026), bringing extensive healthcare experience including CSL Limited leadership roles. Two senior healthcare-pedigreed appointments in quick succession is not coincidence.
4. NovoSorb MTX gaining traction. The 195% H1 growth in the MTX product (FDA cleared) suggests the company is successfully diversifying beyond BTM. A second commercial product at scale fundamentally de-risks the single-product concern that bears have cited.
5. European expansion continuing. On 1 February 2026 (ASX announcement), PNV appointed Arbor Vitae International LLC as distributor across eight Balkan markets, reaching approximately 22 million people. A capital-light approach to extending the commercial footprint.
6. Director buying. Per ASX Appendix 3Y filings: Andrew Lumsden acquired 100,000 shares for $91,364 on 24 February 2026, doubling his holding from 100,000 to 200,000 shares. Robert Douglas acquired 151,000 shares on 12 March 2026 — opening a position from zero. These aren't token buys; directors with full visibility into the business are putting meaningful personal capital in.
The Mechanics of What Happens Next
There are three scenarios from here:
Scenario A: The Unwind Continues (Bull Case)
The 23.9 million shares already covered were likely the weakest shorts — those who built at elevated prices and are most vulnerable to marking losses. If PNV delivers another strong result, or if any pipeline catalyst materialises (MTX US adoption data, diabetes programme update), the remaining 77 million shares face a genuine squeeze dynamic. The 22.7 days-to-cover figure becomes explosive if daily volume picks up.
Scenario B: Partial Cover, Then Stalemate
Some shorts cover into any strength, but the most convicted bears hold their ground. The stock stabilises in the $1.10–$1.30 range with short interest declining gradually to 8–9%.
This is probably the base case. Squeezed enough to hurt the recent shorts, but not explosive enough to flush out the deep-pocketed early-movers who are still in profit.
Scenario C: Rebuild (Bear Case)
If H2 results disappoint or if US sales decelerate sharply, shorts rebuild. We've seen this playbook before — September 2025's squeeze was followed by a complete short rebuild within weeks.
The difference from September 2025: the stock has recovered significantly from its lows, and the fundamental datapoints (MTX growth, CSL hires, director buying) are incrementally more positive. Rebuilding above $1.25 is a harder conviction call than rebuilding from $0.90.
The Numbers in Context
| Metric | Value |
|---|---|
| Current short % | 11.15% (from 14.61% peak) |
| Shares still short | 77.0M |
| Short liability (AUD) | $96.7M |
| Current price | $1.255 |
| Market cap | $867M |
| Days to cover | 22.7 |
| Avg daily volume (30d) | 3.5M shares |
| 52-week high | $1.665 |
| 52-week low | $0.865 |
| Distance from 52-wk high | -25% |
| ASX short rank | #11 (was #4 in March) |
Data sourced from ASIC short position disclosures via ASXShort.app. Latest report date: 25 May 2026.
The 52-week picture is telling: from a $0.865 low to a $1.665 high, PNV has oscillated violently. Today's $1.255 puts it roughly midway between those extremes. If the covering continues and sentiment normalises, the high is the natural magnet. If shorts rebuild and the growth story cracks, the low gets retested.
The September 2025 Precedent: How Shorts Recovered Before
This is the most important thing to understand about PNV's short dynamics. In September 2025, we saw a 17.1 million share cover in a single day (the index removal event). Within six weeks, shorts had rebuilt above 10%. Within four months, they were at all-time highs.
The current cover is 24 million shares over 10 days — faster and larger. But the mechanism is different. The September cover was opportunistic (using index rebalancing volume). This cover appears more fundamental — driven by results, changing narrative, and rising price. Fundamental covers tend to be stickier than opportunistic ones.
Bears who built near PNV's highs are watching those gains compress as 24 million shares have been covered and the stock holds well off its lows. Even those who entered at lower levels now face a changed fundamental picture: the H1 results held up, two CSL-pedigreed hires have been made, and an ASX price query has spotlighted the stock. The question every remaining short is asking: is the H2 FY26 thesis intact enough to hold through the current pressure?
What to Watch From Here
1. The June short reports. ASIC publishes short position data with a T+4 lag. Watch whether the cover continues through June — a second wave of covering would signal that the May event was the start of an unwind, not a one-off.
2. H2 FY26 results. PNV doesn't publish quarterly updates, but conference presentations, AGM trading updates, or any operational announcement that gives visibility on H2 trajectory could be a material catalyst in either direction.
3. Daily short sale volumes. ASXShort.app shows daily short sales for PNV. If daily short sales drop consistently below 200K–300K (from recent peaks of 1–2 million), it signals the aggressive new shorting has stopped. If short sales run high alongside falling short interest, it means old shorts covering while new ones pile in — a more unstable dynamic.
4. NovoSorb MTX US update. The FDA 510(k) clearance is relatively recent. Every new hospital or burn centre that adopts MTX is incremental revenue that shorts need to explain away. Watch for any commercialisation announcements.
5. Director activity. Andrew Lumsden and Robert Douglas recently bought at lower prices. Any further buying above $1.20 would be an exceptionally strong insider signal given they could have bought more cheaply and chose not to.
Track PNV Short Interest in Real Time
ASXShort.app provides daily ASIC short position data, daily short sale volumes, director trades, securities lending data, and squeeze candidate rankings — all free, all in one place.
Compare PNV against other high-short-interest healthcare names on our squeeze candidates screen or see where PNV ranks on days to cover.
All short position data sourced from ASIC mandatory short position disclosures, aggregated and published on ASXShort.app. Director trade data sourced from ASX Appendix 3Y/3X filings. Securities lending data sourced from ASX substantial holder disclosures. This post is for informational purposes only and is not financial advice. Short covering dynamics, squeeze setups, and squeeze outcomes are inherently uncertain. Past squeeze events are not predictive of future ones. Conduct your own research and consult a qualified financial adviser before making investment decisions.
Last updated: 29 May 2026.